2. Gene
  3. C9 - complement C9 Gene

C9 - complement C9 Gene

  • Gene
  • Protein
  • Disease
  • Agent
  • Ortholog
Homo sapiens

Also known as C9D; ARMD15

Gene ID: 735 | Gene type: protein coding

About C9

Cytogenetic location: 5p13.1 Genomic coordinates (GRCh38): 5:39,284,140-39,364,495 (from NCBI)

This gene has 7 transcripts (splice variants), 190 orthologues, 39 paralogues and is associated with 4 phenotypes. Restricted expression toward liver (RPKM 365.0).

Summary

This gene encodes the final component of the Complement System. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on Bacterial membranes to form a pore, permitting disruption of Bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009]

C9 Products(1)

mRNA Protein Name
NM_001737.5 NP_001728.1 complement component C9 preproprotein
Gene Ontology
  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence Reference Source
enables protein binding IPI
IPI: Inferred from physical interaction
28514442 GOA
Biological Process GO Annotation Evidence Reference Source
involved in cell killing IDA
IDA: Inferred from direct assay
26841934 GOA
involved in protein homooligomerization IDA
IDA: Inferred from direct assay
26841934 GOA
Cellular Component GO Annotation Evidence Reference Source
located in extracellular space IDA
IDA: Inferred from direct assay
22832194 GOA
part of membrane attack complex IDA
IDA: Inferred from direct assay
22832194 GOA
part of membrane attack complex IPI
IPI: Inferred from physical interaction
30552328 GOA
located in plasma membrane IDA
IDA: Inferred from direct assay
26841934 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

C9 Protein Structure

TSP_1

TSP_1: Thrombospondin type 1 domain (46 - 94)

Ldl_recept_a

Ldl_recept_a: Low-density lipoprotein receptor domain class A (100 - 134)

MACPF

MACPF: MAC/Perforin domain (272 - 501)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 559 a.a.
Protein Preferred Names Protein Names

complement component C9

complement component 9

Related Diseases

Diseases Alias
Complement Component 9 Deficiency

C9 Deficiency

C9D

C9 Deficiency With Dermatomyositis
Macular Degeneration, Age-Related, 15

Age Related Macular Degeneration 15

ARMD15

Macular Degeneration, Age-Related, 15, Susceptibility To

Macular Degeneration, Age-Related, Type 15
Immunodeficiency Due To A Late Component Of Complement Deficiency

Immunodeficiency Due To C5 To C9 Component Complement Deficiency

Terminal Complement Pathway Deficiency
Meningococcal Meningitis

Meningitis, Meningococcal

Meningitis Meningococcal

Epidemic Meningitis

Meningitis Due To Neisseria Meningitidis

Meningococcal Meninges Infection

Meningococcal Meningeal Infection

Meningococcal Cerebrospinal Inflammation

Chronic Meningococcal Arachnoiditis

Meningococcal Arachnoiditis

Diplococcal Spinal Meningitis

Diplococcal Meningitis

Meningococcal Cerebrospinal Fever

Meningococcal Cerebrospinal Infection

Meningococcal Spinal Meningitis
Immunoglobulin Heavy-And-Light Chain

Ah/Al Amyloidosis

Ig Heavy-And-Light-Chain Amyloidosis
Eye Disease

Eye Diseases

Abnormality Of The Eye

Toxoplasma Oculopathy
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

Approval
Bioactive Molecules (10)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-17356 Fenofibrate 99.93% Yes
HY-N6972 Cepharanthine 99.91% Yes
HY-B1218 Sulfaphenazole Inhibitor 99.83% Unkown
HY-B0258 Gemfibrozil 99.91% Yes
HY-B0281A Ranitidine hydrochloride 99.88% Yes
HY-13463 Avatrombopag Agonist 99.83% Yes
HY-100386 Ticlopidine Inhibitor 99.34% Unkown
HY-B0693 Ranitidine ≥97.0% Yes
HY-13463B Avatrombopag hydrochloride Agonist 96.69% Yes
HY-13463A Avatrombopag maleate Agonist 99.88% Yes
Clinical Phase
Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-N1201 Apigenin 99.58% Phase 2
HY-106379 Lurosetron Antagonist / Phase 2
HY-12946 BI 653048 Inhibitor 99.84% Phase 1
HY-114415 AWZ1066S Inhibitor 98.64% Phase 1
HY-12946A BI 653048 phosphate Inhibitor / Phase 1
Pre-clinical Phase
Bioactive Molecules (140)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-103661 BI-6C9 Inhibitor 98.47% Unkown
HY-N0043 Ginsenoside Rd Inhibitor 99.88% Unkown
HY-N0904 Ginsenoside C-K Inhibitor 99.92% Unkown
HY-15550S 4'-Hydroxy diclofenac-d4 98.92% Unkown
HY-100738 Ubiquitin Isopeptidase Inhibitor I, G5 Inducer ≥98.0% Unkown
HY-N0893 Tetrahydrocurcumin 99.43% Unkown
HY-117389 Homocarbonyltopsentin 99.88% Unkown
HY-15550 4'-Hydroxy diclofenac 99.70% Unkown
HY-15565 APD668 99.10% Unkown
HY-117026 LKY-047 Inhibitor 98.85% Unkown
HY-148907 CS640 Inhibitor 99.43% Unkown
HY-14362 GSK-25 Inhibitor 99.68% Unkown
HY-100641S 4-Hydroxytolbutamide-d9 99.29% Unkown
HY-139345 (S,R,S)-AHPC-CO-C9-acid Chemical 97.64% Unkown
HY-148822 Nampt activator-2 Activator 98.80% Unkown
HY-153898 rTRD01 Inhibitor ≥97.0% Unkown
HY-N1446S Oleic acid-13C 99.95% Unkown
HY-114759 MS-PPOH Inhibitor 99.27% Unkown
HY-17356R Fenofibrate (Standard) 99.91% Unkown
HY-N0473S3 L-Tyrosine-13C9 99.81% Unkown
HY-42034 Hydroquinine 99.84% Unkown
HY-N0688 Linderane Inhibitor 99.61% Unkown
HY-107372S Uridine triphosphate-13C9,15N2 sodium / Unkown
HY-113359AS2 Uridine 5'-diphosphate-13C9,15N2 dilithium Agonist 99.5% Unkown
HY-124352 2-Nonyl-3-hydroxy-4-quinolone ≥98.0% Unkown
HY-125818S3 Cytidine-5'-triphosphate-13C9 dilithium 99.0% Unkown
HY-B0158S7 Cytidine-13C9 Chemical 99.10% Unkown
HY-N0215S11 L-Phenylalanine-13C9,15N Antagonist 99.52% Unkown
HY-128859 EMT inhibitor-2 Inhibitor 99.55% Unkown
HY-B0258S Gemfibrozil-d6 98.00% Unkown
HY-107372S2 Uridine triphosphate-13C9 dilithium ≥98.0% Unkown
HY-116862 Dibenzylfluorescein 99.54% Unkown
HY-18063 ML252 Inhibitor 99.9% Unkown
HY-B0258R Gemfibrozil (Standard) 99.90% Unkown
HY-D0184S3 2'-Deoxycytidine-13C9,15N3 / Unkown
HY-N1201S Apigenin-d5 98.90% Unkown
HY-N7057S3 Nonanoic acid-d2 98.63% Unkown
HY-N8382 Chalepensin Inhibitor ≥98.0% Unkown
HY-W013175S2 Uridine 5'-monophosphate-13C9,15N2 disodium ≥99.0% Unkown
HY-Y0123S DL-Tyrosine-13C9,15N ≥98.0% Unkown
HY-131495 (S)-6-O-Desmethylnaproxen / Unkown
HY-159191S VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI TFA 95.41% Unkown
HY-D1422 ER Thermo Yellow / Unkown
HY-W751165 Uridine-13C9,15N2 / Unkown
HY-135390 Hydroxy desmethyl Bosentan / Unkown
HY-100386S Ticlopidine-d4 Inhibitor / Unkown
HY-100641 4-Hydroxytolbutamide / Unkown
HY-101400S2 Deoxycytidine triphosphate-13C9,15N3 dilithium Activator / Unkown
HY-101400S4 Deoxycytidine triphosphate-13C9 dilithium Activator / Unkown
HY-101981S3 Uridine 5'-monophosphate-13C9,15N2 dilithium / Unkown
HY-101981S4 Uridine 5'-monophosphate-13C9 dilithium / Unkown
HY-113359AS1 Uridine 5'-diphosphate-13C9 dilithium Agonist / Unkown
HY-113400S1 Cytidine diphosphate-13C9 dilithium / Unkown
HY-113400S2 Cytidine diphosphate-13C9,15N3 dilithium / Unkown
HY-113887 Prostaglandin F1β / Unkown
HY-113887A 11β-Prostaglandin F1β / Unkown
HY-116095 CypD-IN-5 Inhibitor / Unkown
HY-119996 AR-C141990 / Unkown
HY-125607 Tetranor-PGJM / Unkown
HY-13463BS Avatrombopag-d8 hydrochloride Agonist / Unkown
HY-138517 Thiol-C9-PEG7 / Unkown
HY-138526 Thiol-C9-PEG4-acid / Unkown
HY-138527 Thiol-C9-PEG4 / Unkown
HY-138528 Thiol-C9-PEG5-acid / Unkown
HY-138529 Thiol-C9-PEG5 / Unkown
HY-141547 Nav1.7-IN-8 Inhibitor / Unkown
HY-141878 di-Ellipticine-RIBOTAC Modulator / Unkown
HY-141913S 3-Chlorotyrosine-13C9, 15N hydrochloride / Unkown
HY-143906 URAT1 inhibitor 2 Inhibitor / Unkown
HY-144652 IDO1-IN-19 Inhibitor 98.52% Unkown
HY-147807 HIV-1 inhibitor-40 Inhibitor / Unkown
HY-148597 FGFR-IN-10 Inhibitor / Unkown
HY-149866 HIV-1 inhibitor-58 Inhibitor / Unkown
HY-150710S Cytidine 5'-triphosphate-13C9,15N3 ammonium / Unkown
HY-151251 CYP2C9/CYP2C19-IN-1 Inhibitor / Unkown
HY-151253 CYP2C1/CYP2C19-IN-2 Inhibitor / Unkown
HY-153371 50-C2-C9-4tail / Unkown
HY-153970 URAT1 inhibitor 7 Inhibitor / Unkown
HY-155265 Pomalidomide-5-C9-NH2 hydrochloride 98.68% Unkown
HY-15550S1 4'-Hydroxy diclofenac-13C6 / Unkown
HY-159143 BChE-IN-33 Inhibitor / Unkown
HY-160555 (S,R,S)-AHPC-CO-C9-NH2 / Unkown
HY-160555A (S,R,S)-AHPC-CO-C9-NH2 hydrochloride 98.79% Unkown
HY-161943 NEU3-IN-1 Inhibitor / Unkown
HY-163208 VH 032 amide-alkylC9-amine hydrochloride / Unkown
HY-163816 Antiproliferative agent-53-d3 Inhibitor / Unkown
HY-169095 (S,R,S)-AHPC-Me-CO-C9-NH2 / Unkown
HY-17356G Fenofibrate (GMP) / Unkown
HY-17356S Fenofibrate-d6 99.70% Unkown
HY-17356S1 Fenofibrate-d4 / Unkown
HY-79131S1 Fmoc-Phe-OH-13C9,15N / Unkown
HY-A0070AS1 Liothyronine-13C9,15N / Unkown
HY-B0158S5 Cytidine-13C9,15N3 / Unkown
HY-B0281AS Ranitidine-d6 hydrochloride 97.00% Unkown
HY-B1422S 9-Aminoacridine-13C6 Inhibitor / Unkown
HY-D0184S5 2'-Deoxycytidine-13C9 / Unkown
HY-N0215S10 L-Phenylalanine-13C9 Antagonist 98% Unkown
HY-N0215S9 L-Phenylalanine-13C9,15N,d8 Antagonist / Unkown
HY-N0893S Tetrahydrocurcumin-d6 / Unkown
HY-N1201R Apigenin (Standard) / Unkown
HY-N6023 Thermopsoside Inhibitor / Unkown
HY-P5538S EPYFGYSGAFK-13C9,15N3 TFA / Unkown
HY-RS01759 C9 Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS01760 C9orf72 Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS01761 C9orf78 Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-RS03460 CYP2C9 Human Pre-designed siRNA Set A Pre-designed Sets / Unkown
HY-U00048 Bucolome Inhibitor 98.93% Unkown
HY-W008016S Fmoc-Tyr(tBu)-OH-13C9,15N / Unkown
HY-W008849S DMT-dC(bz) Phosphoramidite-13C9,15N3 / Unkown
HY-W009162S1 Cytidine 5′-monophosphate-13C9 dilithium / Unkown
HY-W009162S5 Cytidine 5′-monophosphate-13C9,15N3 dilithium / Unkown
HY-W009216S1 2'-Deoxycytidine-5'-monophosphoric acid-13C9,15N3 dilithium / Unkown
HY-W011090S ((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-13C9,15N3 sodium / Unkown
HY-W015007S Metyrosine-13C9,15N,d7 Inhibitor / Unkown
HY-W018386S1 3-​Bromo-​L-​tyrosine-13C9 / Unkown
HY-W042357S4 Ac-rC Phosphoramidite-13C9 / Unkown
HY-W042357S6 Ac-rC Phosphoramidite-13C9,15N3 / Unkown
HY-W048482S1 rU Phosphoramidite-13C9,15N2 / Unkown
HY-W048482S2 rU Phosphoramidite-13C9 / Unkown
HY-W127393 N-Nonanoyl-L-homoserine lactone / Unkown
HY-101399S γ-Glu-(Phe-13C9,15N) / Unkown
HY-116601 6-Hydroxywarfarin / Unkown
HY-117160 4-trans-Hydroxy-glibenclamide Inhibitor / Unkown
HY-117925 Personalised postprandial-targeting / Unkown
HY-124209 9-keto Fluprostenol / Unkown
HY-145490 trans-Hydroxy Glimepiride / Unkown
HY-149566 Thalidomide-5-O-C9-NH2 hydrochloride 99.59% Unkown
HY-149572 Thalidomide-4-O-C9-NH2 hydrochloride / Unkown
HY-150712S Uridine triphosphate-13C9,15N2 dilithium / Unkown
HY-156133 Dihydrospinosyn A aglycone / Unkown
HY-156159 Thalidomide-NH-C9-NH2 hydrochloride / Unkown
HY-164031 Cloperidone Inhibitor / Unkown
HY-169119 Antifungal agent 114 Inhibitor / Unkown
HY-17356S2 Fenofibrate-13C6 / Unkown
HY-18063A ML252 hydrochloride Inhibitor / Unkown
HY-B0258S1 Gemfibrozil-d6-1 / Unkown
HY-B1449S11 Uridine-13C9 / Unkown
HY-N12962 11S(12R)-EET / Unkown
HY-N12962A 11R(12S)-EET / Unkown
HY-113623 Pyrenophorol / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99141 Anti-Mouse LAG-3 Antibody (C9B7W) 95.00% Unkown

Orthologs Information

Species Symbol Source ID
Mus musculus C9 MGD MGI:1098282
Felis catus C9 VGNC VGNC:60238
Macaca mulatta C9 VGNC VGNC:70482
Rattus norvegicus C9 RGD RGD:620319
Bos taurus C9 VGNC VGNC:26647
Canis familiaris C9 VGNC VGNC:38603
Macaca fascicularis C9 NCBI NCBI:102137382
Others C9 NCBI